

A simple fluorescent assay for the discovery of protein-protein interaction inhibitors

**Mona Al-Mugotir<sup>1</sup>, Carol Kolar<sup>2</sup>, Krysten Vance<sup>2</sup>, David L. Kelly<sup>2</sup>, Amarnath Natarajan<sup>2</sup>,  
Gloria E. O. Borgstahl<sup>1,2\*</sup>**

From the <sup>1</sup>University of Nebraska Medical Center, Department of Biochemistry and Molecular Biology, 985870 Nebraska Medical Center, Omaha, NE 68198-5870; <sup>2</sup>University of Nebraska Medical Center, The Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, 986805 Nebraska Medical Center, Omaha, NE 68198-6805

\*To whom correspondence should be addressed: Gloria Borgstahl: University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198-6805; [gborgstahl@unmc.edu](mailto:gborgstahl@unmc.edu); Tel. (402) 559-8578.

## SUPPORTING INFORMATION

Figure S1. Details of EGFP and EGFP-RAD52 expression plasmids and proteins

### EGFP (MW = 29.1 kDa)

MGSSHHHHHH SSGLVPRGSH MVSKGEELFT GVVPILEVELD GDVNGHKFSV 50  
SGEGEGDATY GKLTTLKFICT TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK 100  
QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEEDTL VNRIELKGID 150  
FKEDGNILGH KLEYNYN SHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA 200  
DHYQQNTPIG DGPVLLPDNH YLSTQSALS K DPNEKRDH MV LLEFVTAAGI 250  
TLGMDELYK 259

Note, the F64L\S65T EGFP mutations are highlighted in **green** and the thrombin cleavage site is underlined.

### EGFP-RAD52 (MW = 76.2 kDa)

MGSSHHHHHH SSGLVPRGSH MVSKGEELFT GVVPILEVELD GDVNGHKFSV 50  
SGEGEGDATY GKLTTLKFICT TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK 100  
QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEEDTL VNRIELKGID 150  
FKEDGNILGH KLEYNYN SHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA 200  
DHYQQNTPIG DGPVLLPDNH YLSTQSALS K DPNEKRDH MV LLEFVTAAGI 250  
TLGMDELYK GSGGSGGSGG SGGMSGTEEA ILGGRDHPA AGGGSVLCFG 300  
QCQYTAEYQ AIQKALRQRL GPEYISSRMA GGGQKVCYIE GHRVINLANE 350  
MFGYNGWAHS ITQQNVDFVD LNNGKFYVGV CAFVRVQLKD GSYHEDVGYG 400  
VSEGLKSKAL SLEKARKEAV TDGLKRALRS FGNALGNCIL DKDYLRSLNK 450  
LPRQLPLEVD LTKAKRQDLE PSVEEARVNS CRPNMALGHP QLQQVTSPSR 500  
PSHAVIPADQ DCSSRSLSS AVESEATHQR KLRQKQLQQQ FRERMEKQQV 550  
RVSTPSAEKS EAAPPAPPVT HSTPVTVSEP LLEKDFLAGV TQELIKTLED 600  
NSEKWAVTPD AGDGVVKPSS RADPAQTSDT LALNNQMVTQ NRTPHSVCHQ 650  
KPQAKSGSWD LQTYADQRT TGNWESHRS QDMKKRKYDP S 691

**Figure S1.** Details of EGFP and EGFP-RAD52 expression plasmids and proteins. All expression plasmids were made by Genscript<sup>®</sup>. Codons were optimized for expression in *Escherichia coli*. Enhanced green fluorescent protein (EGFP) was cloned into the pET28a plasmid using the NdeI site so that a thrombin cleavable, 6X His tag was placed at the N-terminus. The NT-EGFP-RAD52 was cloned into pET28a in a similar manner. For the later construct a disordered soluble linker was inserted between EGFP and RAD52. Note, the amino acid sequences with a dotted underline are disordered in the EGFP crystal structure (PDB ID 2Y0G). The soluble disordered linker has a double underline and the human RAD52 sequence is highlighted in **yellow**.